Lung Cancer Considered

Lung Cancer Considered

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by Current sponsors: • AbbVie • AstraZeneca • Gilead • J&J • Summit

Tämä podcast on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi podcastin jaksot saattavat sisältää mainontaa.

Jaksot(393)

FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marc...

2 Huhti 202447min

ELCC 2024 Highlights

ELCC 2024 Highlights

This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Prague. Host Dr. Stephen Liu discusses the important research presented at the meeting with D...

28 Maalis 202458min

Emerging Agents In Small Cell Lung Cancer

Emerging Agents In Small Cell Lung Cancer

Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive-stage disease. Unlike non-small cell lung cancer, treatments are more limited. Fo...

19 Maalis 202441min

Radiopharmaceuticals and Lung Cancer

Radiopharmaceuticals and Lung Cancer

This episode of Lung Cancer Considered focuses on radiopharmaceuticals-- a unique class of drugs that may have the most immediate impact in neuroendocrine tumors. Host Dr. Stephen Liu leads a discuss...

5 Maalis 202454min

FDA Approval: 1L Amivantamab plus Chemotherapy for EGFR Exon 20 NSCLC

FDA Approval: 1L Amivantamab plus Chemotherapy for EGFR Exon 20 NSCLC

Amivantamab Approved by FDA today, March 1! In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCL...

1 Maalis 202428min

Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC

Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC

Today’s episode of Lung Cancer Considered is part of our special series on seminal trials in thoracic oncology, focusing on the phase I study of the PD-1 inhibitor nivolumab. Hosts Dr. Narjust Florez ...

29 Helmi 202432min

From the Basics to Next Line Therapy: ALK + NSCLC

From the Basics to Next Line Therapy: ALK + NSCLC

ALK fusions represent 3-5% of newly diagnosed non-small cell lung cancers but several therapeutic options do exist. Lung Cancer Considered host Dr. Narjust Florez and guests Dr. Christine Lovly from ...

27 Helmi 202446min

Best Practice for RET NSCLC

Best Practice for RET NSCLC

Lung Cancer Considered Host Dr. Stephen Liu moderates a discussion in this podcast on RET as a therapeutic target. RET fusions are a known actionable alteration and this field has blossomed very quick...

20 Helmi 202434min

Suosittua kategoriassa Tiede

rss-mita-tulisi-tietaa
hippokrateen-vastaanotolla
utelias-mieli
docemilia
filocast-filosofian-perusteet
rss-tiedetta-vai-tarinaa
rss-totuuden-liepeilla
tiedekulma-podcast
ihanat-ipanat
radio-antro
rss-bios-podcast
rss-vaasan-yliopiston-podcastit
rss-ammamafia
rss-hereilla
rss-kasvikutsut